乙型肝炎肝硬化失代偿期初始拉米夫定和阿德福韦酯联合抗病毒治疗的疗效观察

耿建章; 范晓红; 陆海英; 李静; 田秀兰; 徐小元

乙型肝炎肝硬化失代偿期初始拉米夫定和阿德福韦酯联合抗病毒治疗的疗效观察

1. 北京大学第一医院感染科
2. 石家庄市第五医院

基金项目:

中国肝炎防治基金会光辉基金(GHF2010205)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 4203
- HTML全文浏览量: 19
- PDF下载量: 1146
- 被引次数: 0
出版历程
- 出版日期: 2011-08-20

The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis

Research funding:

摘要

摘要: 目的研究拉米夫定（LAM）初始联合阿德福韦酯（ADV）治疗乙型肝炎肝硬化失代偿期患者的疗效与安全性。方法 30例HBeAg阳性乙型肝炎肝硬化失代偿期患者,分为LAM初始联合ADV治疗组和变异后联合组,疗程均为48周。结果初始联合组与变异后联合组患者ALT与TBil在治疗4、12、24与48周均较基线明显好转（P<0.05）,治疗4、12周后,两组均无HBV DNA转阴的患者,治疗24周后,分别有4例（40%）初始联合组与4例（20%）变异后联合组患者HBV DNA转阴,但差异无统计学意义。治疗48周后,初始联合组与变异后联合组HBV DNA转阴率分别为90%（9/10）与40%（8/20）,HBeAg/抗-HBe血清转换率分别为60%（6/10）与20%（4/20）,两组间差异均具有统计学意义（P<0.05）。初始联合组患者Child-Pugh评分在48周时,优于变异后联合组（P<0.05）。结论 ADV初始联合LAM治疗在改善乙型肝炎肝硬化失代偿期患者临床状况及抗病毒方面均明显优于变异后联合治疗。
- 肝硬化 /
- 肝炎,乙型 /
- 抗病毒药 /
- 拉米夫定 /
- 阿德福韦酯
Abstract: Objective To evaluate the efficacy and safety of de novo combination therapy with lamivudine and adefovir dipivoxil in the treatment patients of chronic hepatitis B with decompensated cirrhosis.Methods Thirty chronic hepatitis B patients with decompensated cirrhosis were enrolled in and divided into two groups, one group (10 patients) was given lamivudine combined with adefovir dipivoxil at the beginning of the therapy, while the other group (control group) was given lamivudine only at the beginning of treatment, then added adefovir dipivoxil on after HBV YMDD mutation.The duration of treatment for both groups was 48 weeks.Results The ALT and TBil levels in these groups were improved after 4, 12, 24, and 48 treatment weeks (P<0.05) .No patient achieved HBV DNA undetectable in these groups after 4 and 12 weeks treatment.However, after 24 weeks treatment, 4 in denovo combination group (40%) and 4 in added-on group (20%) achieved HBV DNA undetectable, respectively (P=0.384) .The undetectable rates of HBV DNA at week 48 were 90% for the denovo combination group and 40% for the controls (P<0.05) .The rates of HBeAg/HBeAb seroconversion were 60% and 20% (P<0.05) , respectively for the denovo combination group and the control.After 48 weeks treatment, Child-Pugh scores in the denovo combination group was better than that in the control group (P<0.05) .Conclusion Lamivudine combined with adefovir dipivoxil at the beginning of the therapy was effective in improving liver function, antiviral effect and Child-Pugh score in chronic hepatitis B with decompensated cirrhosis patients.
- liver cirrhosis /
- hepatitis B /
- antiviral agents /
- lamivudine /
- adefovir dipivoxil

HTML全文

参考文献(9)

[1] 中华医学会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13 (12) :881-891.

[2]Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patients withchronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.

[3]张月荣, 张月萍, 张涛.失代偿期肝硬化抗病毒治疗的临床价值[J].临床肝胆病杂志, 2006, 22 (02) :111-112.

[4]曾伟群, 郭树华, 张大志, 等.拉米夫定治疗活动期肝炎肝硬化的疗效观察[J].中华肝脏病杂志, 2003, 11 (3) :176-178.

[5]Lok AS, Lai CL, Leung N, et al.Long-term safety of lamivudinetreatment in patients with chronic hepatitis B[J].Gastroenterology, 2003, 125 (6) :1714-1722.

[6]姚光弼, 王宝恩, 崔振宇, 等.拉米夫定治疗慢性乙型肝炎三年疗效观察[J].中华内科杂志, 2003, 42 (6) :382-387.

[7]姚光弼, 崔振宇, 姚集鲁, 等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验[J].中华肝脏病杂志, 2003, 11 (2) :103-108.

[8]Dienstag JL, Goldin RD, Heathcote EJ, et al.Histological outcomeduring long-term lamivudine therapy[J].Gastroenterology, 2003, 124 (1) :105-117.

[9]Macellin P, Chang TT, Lim S, et al.Adefovir dipivoxil for the treat-ment of hepatitis B e antigen-positive chronic hepatitis B[J].N Engl JMed, 2003, 348 (9) :808-816.

施引文献

资源附件(0)

访问统计